Scientists and transplant clinicians at the Ansary Stem Cell Institute at Weill Cornell Medical College and the Center for Cell Engineering at Memorial Sloan Kettering Cancer Center have been awarded a $15.7 million, four-year research grant from the New York State Stem Cell Science Program (NYSTEM).
The scientists will translate their approach to manipulate hematopoietic stem cells to cure acquired and inherited blood disorders. For many patients with such blood diseases, including sickle cell disease, the only hope for a cure requires transplanting normal blood stem cells.
But in many instances suitable blood stem cells cannot be found or there are
The Gamida Cell-Teva Joint Venture Concludes Enrollment for the Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
The results of the StemEx study are expected during the second half of 2012
Gamida Cell announced today that the Gamida Cell-Teva Joint Venture (JV), equally held by Gamida Cell and Teva Pharmaceutical Industries, has enrolled the last of 100 patients in the international, multi-center, pivotal registration, Phase III clinical trial of StemEx, a cell therapy product in development as an alternative therapeutic treatment for adolescents and adults, with blood cancers such as leukemia and lymphoma,
In an interview with ETHealthworld, Dr. Sachin Jadhav, Group In-charge – Haematology & Bone Marrow Transplantation, Gleneagles Global Hospitals, Bengaluru, talks about the innovations and challenges seen in this field.
What is Bone marrow transplant and how is India placed in this field? How do you see it globally?
Bone marrow transplant (BMT) is when we change the bone marrow. Bone marrow is what is present inside the bones and is a factory where all the blood cells are manufactured or created. Inside the bone marrow, we have stem cells which are like a seed that gives rise to red cells,
Using a patient’s own stem cells, researchers at Johns Hopkins have corrected the genetic alteration that causes sickle cell disease (SCD), a painful, disabling inherited blood disorder that affects mostly African-Americans. The corrected stem cells were coaxed into immature red blood cells in a test tube that then turned on a normal version of the gene.
The research team cautions that the work, done only in the laboratory, is years away from clinical use in patients, but should provide tools for developing gene therapies for SCD and a variety of other blood disorders.
In an article published online August 31 in
Image via Wikipedia
Researchers in the U.S. say they may have found a new and better source for harvesting stem cells: the placentas that are often discarded after birth.
The research from Children’s Hospital & Research Center Oakland found there are far more stem cells in placentas than in umbilical cord blood, the traditional source for stem cells, and they can be safely extracted for transplantation.
“Yes, the stem cells are there; yes, they are viable; and yes, we can get them out,” declared Dr. Frans Kuypers, one of the scientists who led the research with fellow scientist Vladimir Serikov.
The study was